EMEA-002469-PIP01-18
Key facts
Active substance |
Pyrimidinyl-aminopyridine dual leucine zipper kinase inhibitor (GDC-0134)
|
Therapeutic area |
Neurology
|
Decision number |
P/0099/2019
|
PIP number |
EMEA-002469-PIP01-18
|
Pharmaceutical form(s) |
Capsule, hard
|
Condition(s) / indication(s) |
Treatment of amyotrophic lateral sclerosis
|
Route(s) of administration |
Oral use
|
Contact for public enquiries |
Roche Registration GmbH
Tel. +41 6168 79411 |
Decision type |
RW: decision refers to a refusal on a request for waiver in all age groups for the listed condition(s)
|